PCRX logo

PCRX Pacira BioSciences, Inc.

NASDAQ Global Select · Drug Manufacturers - Specialty & Generic · Healthcare

$36.48
+0.02 (+0.05%)

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the…

Market Cap: $1.46Bwww.pacira.com

Price

No data yet.

Social Signal Score

57
5d
—
30d
50
1 mentions
—
60d
60
5 mentions
—
90d
60
5 mentions
—
news: 5

Analyst Ratings

36 analysts
Holdconsensus
Strong Buy 0Buy 11Hold 22Sell 3Strong Sell 0
Avg price target$31.6-13.4%
Low $25Median $32High $36.5
Current Consensus

Revenue

$176.65M+142.32%
$67.33M$110.51M$153.69M$196.87M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$2.95
$2.91–$3.02
5 analysts
FY2026
$2.90-2% YoY
$2.85–$2.98
4 analysts
FY2027
$3.51+21% YoY
$3.22–$3.73
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Frank D. Lee
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
827
Beta
0.25
Country
US
Piotroski score
7 / 9 (Strong)
Altman Z-score
2.81
www.pacira.com